Vyriad, Imanis Ink Cancer Companion Dx Development Deal

Aug 16, 2016

|

NEW YORK (GenomeWeb) – Vyriad announced today that it has partnered with Imanis Life Sciences to develop in vitro and in vivo tests to predict a patient's likelihood of responding to its oncolytic virus therapeutics.

Vyriad is developing cancer treatments that use vesicular stomatitis and measles viruses modified with genes encoding known tumor antigens in order to trigger anticancer immune responses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Maybe Not to Eat…

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Moving From DC to KC

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Just for Fun?

Slate's Jane Hu compares some at-home genetic tests to astrology.

PLOS Has Skin Cancer Risk Scores and More This Week

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.

Featured White Papers

BlueBee Data Security & Compliance

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jun

18

Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.

Jun

19

Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jun

25

Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Menu